Parathyroid hormone-related protein (PTHrP) gene expression and/or immunoreactive protein have previously been identified in the uterus and intrauterine gestational tissues. The putative roles of PTHrP during pregnancy include vasodilatation, regulation of placental calcium transfer, uterine smooth muscle relaxation and normal fetal development. The aims of this study were 1) to determine the tissue-specific and temporal expression of PTHrP mRNA and immunoreactive protein in human gestational tissues collected at preterm and term; and 2) to determine the effect of labour on PTHrP expression by collecting these tissues from women undergoing elective caesarean section (before labour), intra-partum caesarean section during spontaneous-onset labour (during labour), and women with spontaneous labour and normal vaginal delivery (after labour). Total RNA and protein were extracted from placenta, amnion (over placenta and reflected) and choriodecidua for analysis by Northern blot (using a specific human PTHrP cDNA probe), and by N-terminal PTHrP RIA respectively. In amnion over placenta, reflected amnion and choriodecidua both PTHrP mRNA relative abundance and immunoreactive protein were significantly elevated at term compared with preterm (P < 0.01). At term, both PTHrP and its mRNA were significantly greater in amnion than in placenta and choriodecidua (P < 0.05). Also, both PTHrP and its mRNA were significantly elevated in amnion over placenta compared with reflected amnion (P < 0.05). The expression of PTHrP and its mRNA did not change in association with term labour or rupture of the fetal membranes, therefore this study provides no evidence for a specific PTHrP role in the onset and/or maintenance of term labour. However, the significant up-regulation of PTHrP mRNA and protein in the fetal membranes at term compared with preterm suggests an important role in late human pregnancy.
During winter (December to March), when late-pregnant ewes were maintained under an artificial long-day photoperiod (16 h light) for 3 weeks or more before insertion of fetal vascular cannulae between 118 and 120 days of gestation (full term, 147 days), plasma prolactin concentrations in their fetal lambs were significantly increased throughout the last 3 weeks of gestation in comparison with values in similar aged fetuses from ewes experiencing only the natural short-day (less than 9 h light) winter photoperiod. When additional lighting was given only after vascular cannulation, fetal plasma prolactin increased steadily from low values, characteristic of winter pregnancies, to high values, characteristic of long-day (16 h light:8 h darkness) pregnancies. Maternal plasma prolactin concentrations changed in a similar way. During summer pregnancies (greater than 16 h light), plasma prolactin in fetal lambs was significantly reduced within 48 h when ewes were given melatonin by i.v. infusion for 14 h each night to simulate the winter duration of the nocturnal increase in plasma melatonin. Maternal plasma prolactin concentrations also decreased significantly when melatonin was given for 3 weeks, but not in a shorter experiment. Increases in fetal plasma prolactin were proportional to the basal prolactin concentration in fetuses injected i.v. with TRH or a dopaminergic antagonist, metoclopramide, to assess how photoperiod influenced the responsiveness of prolactin secretion to acute stimulation. The results confirm that photoperiod, rather than developmental maturity, is the principal determinant of plasma prolactin in the fetal lamb during the last third of gestation, and provide evidence that photoperiodic information is transmitted to the fetus through the diurnal rhythm of melatonin in the ewe.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.